Cytoreductive Nephrectomy May Still Remain Standard For Some With Metastatic Renal Cell Carcinoma
The addition of cytoreductive nephrectomy to treatment with sunitinib malate did not provide a survival benefit for intermediate and poor-risk patients with metastatic renal cell carcinoma, according to results of the phase 3 CARMENA clinical trial presented at ASCO Annual Meeting.08/06/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Kidney Cancer | Nephrectomy | Renal Cell Carcinoma | Urology & Nephrology